November 28, 2016 - By Louis Casey
Thomas Anderson is the See Remarks of Sage Therapeutics Inc. He lately sold 10,000 shares in the ‘s company with the trade value amounting to around $550,000 USD. The stated number is according to the traded price of $55.0 for each share.
Out of 10 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 8 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 80% are positive. $90 is the highest target while $18 is the lowest. The $68.75 average target is 36.38% above today’s ($50.41) stock price. SAGE Therapeutics has been the topic of 11 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) has “Buy” rating given on Thursday, September 3 by JP Morgan. The firm has “Sell” rating given on Tuesday, May 24 by Chardan Capital Markets. On Thursday, September 3 the stock rating was maintained by Leerink Swann with “Buy”. Lake Street initiated SAGE Therapeutics Inc (NASDAQ:SAGE) rating on Friday, March 11. Lake Street has “Buy” rating and $90 price target. Stifel Nicolaus initiated SAGE Therapeutics Inc (NASDAQ:SAGE) on Monday, November 14 with “Buy” rating. The firm has “Outperform” rating by BMO Capital Markets given on Wednesday, June 29. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, March 30. The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) has “Outperform” rating given on Tuesday, September 13 by Raymond James. The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) has “Buy” rating given on Thursday, June 23 by H.C. Wainwright.
Insitutional Activity: The institutional sentiment decreased to 1.47 in Q2 2016. Its down 0.04, from 1.51 in 2016Q1. The ratio fall, as 28 funds sold all SAGE Therapeutics Inc shares owned while 27 reduced positions. 23 funds bought stakes while 60 increased positions. They now own 29.30 million shares or 2.83% more from 28.49 million shares in 2016Q1.
Bb Biotech Ag owns 850,639 shares or 1.01% of their US portfolio. The Pennsylvania-based Sei has invested 0% in SAGE Therapeutics Inc (NASDAQ:SAGE). Rockefeller Financial Services holds 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE) for 2,257 shares. State Board Of Administration Of Florida Retirement System has 10,316 shares for 0% of their US portfolio. Blackrock Institutional Na holds 491,527 shares or 0% of its portfolio. Impact Advisors holds 7,768 shares or 0.11% of its portfolio. Great Point Lc, a Connecticut-based fund reported 330,000 shares. Checchi Capital Advisers Limited Liability Corporation last reported 0% of its portfolio in the stock. Secor Advsrs L P has 0.07% invested in the company for 19,461 shares. Northern Trust accumulated 283,797 shares or 0% of the stock. Morgan Stanley reported 71,788 shares or 0% of all its holdings. Jefferies Grp Inc Ltd Liability Co has 0.01% invested in the company for 43,110 shares. Nationwide Fund Advsr accumulated 29,000 shares or 0% of the stock. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 569 shares in its portfolio. Legal General Group Public Ltd Com owns 5,414 shares or 0% of their US portfolio.
Insider Transactions: Since July 12, 2016, the stock had 0 buys, and 5 insider sales for $1.51 million net activity. Robichaud Albert sold $880,000 worth of stock. IGUCHI KIMI also sold $75,885 worth of SAGE Therapeutics Inc (NASDAQ:SAGE) on Friday, November 11.
About 321,918 shares traded hands. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 37.03% since April 25, 2016 and is uptrending. It has outperformed by 31.02% the S&P500.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $1.90 billion. The Firm is engaged in developing and commercializing medicines to treat central nervous system disorders. It currently has negative earnings. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.
According to Zacks Investment Research, “SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.”
Analysts await SAGE Therapeutics Inc (NASDAQ:SAGE) to report earnings on February, 22. They expect $-1.14 earnings per share, down 15.15% or $0.15 from last year’s $-0.99 per share. After $-1.15 actual earnings per share reported by SAGE Therapeutics Inc for the previous quarter, Wall Street now forecasts -0.87% EPS growth.
More notable recent SAGE Therapeutics Inc (NASDAQ:SAGE) news were published by: Fool.com which released: “Here’s Why SAGE Therapeutics Inc. Is Surging Today” on July 12, 2016, also Streetinsider.com with their article: “Form 4 Sage Therapeutics, Inc. For: Nov 15 Filed by: Anderson Thomas” published on November 28, 2016, Prnewswire.com published: “Sage Therapeutics, Inc. – Product Pipeline Review – 2016” on September 27, 2016. More interesting news about SAGE Therapeutics Inc (NASDAQ:SAGE) were released by: Valuewalk.com and their article: “SAGE Therapeutics Inc (SAGE) – Debunking Asclepia Capital” published on April 01, 2016 as well as Fool.com‘s news article titled: “Here’s Why Sage Therapeutics’ Stock Is Falling Today” with publication date: March 23, 2016.
SAGE Therapeutics, Inc., incorporated on April 16, 2010, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Firm is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey